Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEALS phase II trial of intravenous NX210c in adults with amyotrophic lateral sclerosis
2023-508895-13-00Phase 2Completed
- Sponsor
- Axoltis Pharma
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing NX210c with Placebo (2 arms). Primary endpoints: Change in serum neurofilament light chain and Change in albumin CSF/serum quotient. Started Oct 2024; status: completed.
02
Drugs
nx210c
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2023-508895-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508895-13-00.